BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32437713)

  • 1. Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells.
    Gong TT; Liu XD; Zhan ZP; Wu QJ
    Exp Cell Res; 2020 Aug; 393(2):112061. PubMed ID: 32437713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells.
    Han X; Zhen S; Ye Z; Lu J; Wang L; Li P; Li J; Zheng X; Li H; Chen W; Li X; Zhao L
    Cell Physiol Biochem; 2017; 41(3):973-986. PubMed ID: 28222434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane.
    Hunakova L; Gronesova P; Horvathova E; Chalupa I; Cholujova D; Duraj J; Sedlak J
    Toxicol Lett; 2014 Nov; 230(3):479-86. PubMed ID: 25159039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.
    Cai Y; An B; Yao D; Zhou H; Zhu J
    Bioengineered; 2021 Dec; 12(2):10713-10722. PubMed ID: 34747309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptolide antagonized the cisplatin resistance in human ovarian cancer cell line A2780/CP70 via hsa-mir-6751.
    Wang R; Ma X; Su S; Liu Y
    Future Med Chem; 2018 Aug; 10(16):1947-1955. PubMed ID: 29966441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
    Li QQ; Xie YK; Wu Y; Li LL; Liu Y; Miao XB; Liu QZ; Yao KT; Xiao GH
    Oncotarget; 2017 Feb; 8(7):12067-12080. PubMed ID: 28076844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
    Hu Z; Cai M; Zhang Y; Tao L; Guo R
    Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
    Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
    Niu Q; Liu Z; Gao J; Wang Q
    Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
    Niu L; Ni H; Hou Y; Du Q; Li H
    Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
    Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
    Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression.
    Deng Y; Zhao F; Hui L; Li X; Zhang D; Lin W; Chen Z; Ning Y
    J Ovarian Res; 2017 Jul; 10(1):50. PubMed ID: 28743276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MZF1 possesses a repressively regulatory function in ERCC1 expression.
    Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
    Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.